Company / Capital Returned to Shareholders
Organon & Co. Capital Returned to Shareholders History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$88.0M
FY2025
5-year range
$0 / $297.0M
FY2021-FY2025
Trend
-70.4%
vs FY2024
Sector context
#26 of 52
Health Care
What the data says
At $88M, Organon & Co.'s capital returned to shareholders ranks #26 of 52 in the Health Care sector. Declined from $294M to $88M over the past 2 years.
Based on SEC 10-K filings.
$88M in FY2025 with a 3-year CAGR of -32.8%.
Declined from $294M to $88M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -32.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#26 of 52 in Health CareTop 50% of 52This company $88.0M Sector average $1.3B
▼
-93.4% below sector average
Key checks
Key Insights
- 3-year CAGR of -32.8%, indicating a declining trend.
- In FY2025, capital returned to shareholders decreased 70.4% year-over-year.
- Ranks #26 out of 52 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $88.0M | -70.4% |
| FY2024 | $297.0M | +1.0% |
| FY2023 | $294.0M | +1.4% |
| FY2022 | $290.0M | - |
| FY2021 | $0 | - |
| FY2020 | $0 | - |
| FY2019 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026